FDA Designates Triojection® as a Breakthrough Device Read More
TORONTO, Aug. 15, 2025 /CNW/ – SpinaFX Medical Inc., (“SpinaFX”) a leading innovator in image-guided interventional spine care, is proud to announce that its flagship device, Triojection®, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This milestone acknowledges Triojection’s potential to offer a highly
We have recently welcomed Jodi Menezes to SpinaFX as Head of Clinical Affairs. Jodi joins us from Johnson & Johnson, with a decade of experience in the MedTech industry, where she has built a strong foundation in driving business growth, operational efficiencies, and strategic market expansion. In her role as Head of Clinical Affairs at
April 10-12, 2025 SpinaFX was honored to participate in the 33rd Interdisciplinary Research Conference on Injectable Osteoarticular Biomaterials and Bone Augmentation (GRIBOI), held at the Fairmont Banff Springs Hotel in Banff, Alberta, Canada. At Booth #3, our team engaged with interventional spine and pain specialists, researchers, and industry leaders from
Banff, Alberta, Canada SpinaFX, a Canadian company focused on developing minimally invasive, image-guided treatments for back pain caused by contained herniated discs, proudly participated in the 33rd Interdisciplinary Research Conference on Injectable Osteoarticular Biomaterials and Bone Augmentation (GRIBOI 2025). Held from April 10 to 12 at the Fairmont Banff Springs